Dynavax to Present at the Cowen 41st Annual Health Care Conference

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company, announced that CEO Ryan Spencer will present at the Cowen 41st Annual Health Care Conference on March 1, 2021, at 3:20 p.m. E.T.

Rhea-AI Summary

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company, announced that CEO Ryan Spencer will present at the Cowen 41st Annual Health Care Conference on March 1, 2021, at 3:20 p.m. E.T. The presentation will be available via webcast on the Company’s investors website. Dynavax is known for its vaccine development, particularly HEPLISAV-B®, approved for hepatitis B prevention in adults, and is advancing CpG 1018 as a vaccine adjuvant for various diseases.

Argus Session date unavailable

+0.41% session move Open Argus

Details

News Market Reaction – DVAX

The recorded move for DVAX in the trading session of this news was +0.41%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Feb. 16, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the Cowen 41st Annual Health Care Conference on Monday, March 1, at 3:20 p.m. E.T.

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-cowen-41st-annual-health-care-conference-301229271.html

SOURCE Dynavax Technologies

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Dynavax's presentation at the Cowen Health Care Conference?

Dynavax's presentation at the Cowen 41st Annual Health Care Conference is scheduled for March 1, 2021, at 3:20 p.m. E.T.

Who is presenting for Dynavax at the Cowen Conference?

CEO Ryan Spencer will be presenting for Dynavax at the Cowen Conference.

How can I watch Dynavax's presentation at the Cowen Conference?

The presentation will be webcasted and can be accessed through the 'Events & Presentations' page in the investors section of Dynavax's website.

What is Dynavax Technologies known for?

Dynavax Technologies is known for developing and commercializing vaccines, including the hepatitis B vaccine HEPLISAV-B®.

What is the stock ticker for Dynavax Technologies?

Dynavax Technologies is traded under the stock symbol DVAX.